A

Amgen

Makes biotech medicines for serious illnesses

Senior Manager Instrumentation and Maintenance

Full-TimeUpdated on 10/24/2026
$141.6k - $191.5k
Expert
Bachelor's, Master's, PhD, Associate's
Holly Springs, NC, USA
In PersonOn-site; up to 10% domestic/international travel.
General Maintenance & RepairEquipment Maintenance

About the job

Requirements
  • A high school diploma or GED and 12 years of engineering experience, or an Associate’s degree and 10 years of engineering experience, or a Bachelor’s degree and 8 years of engineering experience, or a Master’s degree and 6 years of engineering experience, or a Doctorate degree and 2 years of engineering experience.
  • At least 2 years of experience directly managing people and/or leadership experience leading teams, projects, or programs, or directing resource allocation; this experience may run concurrently with required technical experience.
  • Strong knowledge of maintenance management and Computerized Maintenance Management Systems.
  • Ability to analyze and improve facilities-related quality systems.
  • Ability to work flexibly as required to support 24/7 operations, including occasional after-hours engineering coverage.
Responsibilities
  • Build and lead a team of Maintenance and Instrumentation professionals and serve as the main point of contact for the Maintenance function during site design, construction, start-up, and operational readiness.
  • Develop and implement long-term technical support strategy for ongoing operations and maintenance of installed systems and equipment, including Computerized Maintenance Management System setups.
  • Support development and implementation of goals, objectives, and budgets for maintenance services, including site maintenance and calibration programs.
  • Ensure Preventive Maintenance and Calibration programs align with current Good Manufacturing Practice, safety requirements, local and global regulations, and maintenance excellence standards.
  • Ensure procedures are in place for current Good Manufacturing Practice and daily activities are followed by area personnel and contractors.
  • Ensure personnel safety during plant construction, start-up operations, and maintenance activities across multiple shifts, providing 24/7 plant and utility coverage.
  • Lead a team of Maintenance and Instrumentation professionals and serve as the main point of contact for the Maintenance and Instrumentation function during site operations.
  • Manage maintenance-related system ownership by providing adequate resources and technical talent and expertise, maintenance procedures, system validation support, performance-data monitoring, training materials, and ensuring operating procedures are followed.
  • Execute maintenance and calibration programs to support 24/7 reliability of plant operations.
  • Ensure site readiness and compliance for internal audits, external agency audits, and partner visits.
  • Lead and support continuous improvement initiatives focused on safety, reliability, efficiency, and sustainability.
  • Maintain and improve plant capability and equipment reliability in partnership with engineering leadership and technical staff.
  • Collaborate with key customers and support groups, including Manufacturing, Quality, Environmental Health & Safety, and Engineering.
  • Oversee and lead complex facilities and maintenance initiatives and projects, and provide expertise and resources for capital project execution.
  • Establish clear expectations and priorities for staff, foster continuous improvement, partnership, and knowledge sharing, provide development opportunities and feedback, and actively listen to staff.
  • Maintain and develop maintenance performance indicators, supervise, assess, and develop staff, and ensure targets and milestones are completed on time and within budget.
  • Participate in the Maintenance budgeting process, including forecasting costs, managing expenditures, and ensuring efficient allocation of resources.
  • Travel domestically and internationally up to 10%.
Desired Qualifications
  • At least 6 years of engineering or maintenance experience in biotechnology, pharmaceuticals, another regulated environment, or military service.
  • At least 3 years of experience ensuring compliance in a highly regulated environment.
  • Interpersonal and facilitation skills and the ability to work in a collaborative, team-based environment.
  • Ability to lead multiple tasks and effectively set priorities.
  • Ability to mentor and develop engineering staff and contribute to a team-based culture that relies on collaboration for effective decision-making.
  • Leadership, technical writing, and communication/presentation skills.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

PR Newswire
Oct 26th, 2026
Amgen appoints former Yum! Brands CEO David Gibbs to its board

Amgen has appointed David W. Gibbs to its board of directors, effective immediately. He will serve on the Audit Committee and the Compensation and Management Development Committee. Gibbs recently retired as president and chief executive officer of Yum! Brands, owner of Taco Bell and Kentucky Fried Chicken. As chief executive from 2020 to 2025, he led its digital transformation and expanded it to nearly 61,000 locations. He has sat on the board of Under Armour since 2021 and PepsiCo since 2026. "His experience creating direct relationships with customers will help inform how we prepare for future launches," said Robert A. Bradway, Amgen's chairman and chief executive officer. The board now has 13 directors, 12 of them independent.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.

Yahoo Finance
Oct 25th, 2026
Amgen vs Gilead: Which biotech dividend stock is the better buy, with yields of 2.2% and 2.1%?

Amgen and Gilead Sciences, two of the few big biotech companies that pay dividends, suit different kinds of income investors, according to a comparison by The Motley Fool's Keith Speights. Amgen offers a forward dividend yield above 2.2%, against slightly below 2.1% for Gilead. Gilead has the lower payout ratio, at 43.5% versus 60.9%, and the cheaper valuation: 15.6 times forward earnings against 16.7. Amgen's product sales grew 9% year over year in its latest quarter, against 8% for Gilead. It has 17 drugs on track to be blockbusters this year, versus eight for Gilead, and 29 late-stage programs. Speights favours Amgen for yield and growth, and Gilead for safety and value.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.